What we do Sakar Healthcare Limited manufactures a broad range of pharmaceutical products including liquid orals, tablets, injectables, and oncology formulations, serving multinational clients globally as a CDMO. |
Founded in 2,004 |
Market share Recognized EU GMP certified pharmaceutical manufacturer with growing exports and oncology product commercialization. |
Problem solved Addresses global demand for quality pharmaceutical formulations and oncology medicines through certified manufacturing and contract manufacturing services. |
Top clients or who we serve Serves multinational pharmaceutical companies and healthcare sectors primarily B2B with expanding export markets in Africa and Europe. |
Key management Sanjay S. Shah (Managing Director), Aarsh S. Shah (Joint Managing Director), Sunil Marathe (Whole-time Director - Technical). |
Our journey and innovations Started manufacturing in 2005; expanded facilities by 2012; obtained EU GMP certification in 2020; launched oncology unit in 2021 with WHO GMP certification in 2022-23; patented IMATINIB. |
Where we operate India-based with export approvals for markets including Uganda, Kenya, Yemen, Ethiopia, and Europe. |
Top products or what we offer Pharmaceutical formulations in analgesics, antibiotics, injectables, oral solids, and oncology products. |
Top brands Selective oncology drugs like IMATINIB with EU GMP certification; multiple dosage forms under contract manufacturing. |
Raw materials needed Active Pharmaceutical Ingredients (APIs), excipients, solvents, and specialized oncology drug components. |
Raw materials supplier Sourced from certified pharmaceutical raw material suppliers; details not specified publicly. |
Recurring vs cyclical contribution Revenue primarily recurring from contract manufacturing and pharmaceutical sales with steady export demand. |
Our industry position Emerging player with strong regulatory compliances, expanding oncology segment, and reputed EU GMP certification supporting growth. |
Financial highlights FY 2024-25 revenue Rs.177.58 crore; Net profit Rs.17.5 crore; consistent year-over-year growth in turnover and profits. |
Geographical revenue split Exports to multiple African and Middle Eastern countries; majority revenue from India and overseas sales. |
Order book Order specifics not disclosed; ongoing contract manufacturing engagements with multinationals and oncology clients. |
Whats driving growth EU GMP certifications, oncology product commercialization, expansion of manufacturing capacity and export market diversification. |
Our future plans Capex focused on lipid complex injections machinery, expansion of oncology manufacturing unit, and increased export footprint. |
Our green promise Committed to environmental safety, compliance with statutory regulations, and sustainable manufacturing processes. |
Our people and values Approximately 342 employees; focus on training, inclusion, corporate governance, and employee safety. |
Key challenges ahead Regulatory compliance, competitive pharmaceutical market, raw material cost volatility, and expansion execution risks. |
Interesting facts First CDMO with patented IMATINIB formulation and EU GMP in oncology niche with multiple manufacturing certifications. |
Risks and strategy Risk management policy in place for operational, compliance, and financial risks; strategy includes diversification and regulatory adherence. |
